Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153992 | 0.85 | TSHR (0.44) | TSHRGLP1REPHX2 | |
| SCHEMBL12201188 | 0.84 | CASP2 (0.58) | EPHX1CASP2FAAHNAAADNM1 | |
| SCHEMBL5547592 | 0.83 | BLM (0.50) | TSHR | |
| SCHEMBL1419838 | 0.83 | SLC6A5 (0.44) | EPHX1CASP2FAAHNAAADNM1 | |
| SCHEMBL3153101 | 0.82 | DNM1 (0.49) | FAAHDNM1CNR1GLP1REPHX2 | |
| SCHEMBL25665817 | 0.82 | FAAH (0.54) | EPHX1CASP2FAAHNAAACNR1 | |
| SCHEMBL3154287 | 0.79 | DGKA (0.49) | FAAHDNM1GLP1REPHX2 | |
| SCHEMBL24950256 | 0.79 | CNR1 (0.57) | CASP2FAAHNAAADNM1CNR1 | |
| SCHEMBL1419654 | 0.79 | CASP2 (0.51) | EPHX1CASP2FAAHNAAADNM1 | |
| SCHEMBL22473787 | 0.79 | FAAH (0.57) | EPHX1CASP2FAAHNAAACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | MARINA BIOTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2296711-A2 | MULTI-ARM AMINES AND USES THEREOF | MDRNA, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009148955-A2 | MULTI-ARM AMINES AND USES THEREOF | MDRNA, INC (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009148955-A2 | MULTI-ARM AMINES AND USES THEREOF | MDRNA, INC (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | SNRPE, SNRPA, ADAR | EPHX1 4429/4885CASP2 3037/4885FAAH 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.